Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taragarestrant - InventisBio

Next Previous
Drug Profile

Taragarestrant - InventisBio

Alternative Names: D 0502

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InventisBio
  • Class Acrylates; Antineoplastics; Chlorobenzenes; Fluorinated hydrocarbons; Hexanes; Indoles; Methylamines; Pentanoic acids; Phenols; Piperidines; Pyridones; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer

Most Recent Events

  • 04 Jan 2026 Jiangsu Alphamab Biopharmaceuticals plans a phase Ib/II trial for HER2-negative breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in China(IV, Infusion), in January 2026 (NCT07336771)
  • 09 Jan 2025 Chemical structure information added.
  • 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top